Peritoneal Effluent Cell-Free DNA Sequencing in Peritoneal Dialysis Patients With and Without Peritonitis

Philip Burnham, Fanny Chen, Alexandre P. Cheng, Vesh Srivatana, Lisa T. Zhang, Emmanuel Edusei, Shady Albakry, Brittany Botticelli, Xunxi Guo, Amanda Renaghan, Jeffrey Silberzweig, Darshana M. Dadhania, Joan S. Lenz, Michael Heyang, Iliyan D. Iliev, Joshua A. Hayden, Lars F. Westblade, Ivjin De Vlaminck,* and John R. Lee*

Rationale & Objective: Conventional culture can be insensitve for the detection of rare infections and for the detection of common infections in the setting of recent antibiotic usage. Patients receiving peritoneal dialysis (PD) with suspected peritonitis have a significant proportion of negative conventional cultures. This study examines the utility of metagenomic sequencing of peritoneal effluent cell-free DNA (cfDNA) for evaluating the peritoneal effluent in PD patients with and without peritonitis.

Study Design: Prospective cohort study.

Setting & Participants: We prospectively characterized cfDNA in 68 peritoneal effluent samples obtained from 33 patients receiving PD at a single center from September 2016 to July 2018.

Outcomes: Peritoneal effluent, microbial, and human cfDNA characteristics were evaluated in culture-confirmed peritonitis and culture-negative peritonitis.

Analytical Approach: Descriptive statistics were analyzed and microbial cfDNA was detected in culture-confirmed peritonitis and culture-negative peritonitis. Descriptive statistics were analyzed and microbial cfDNA was detected in culture-confirmed peritonitis and culture-negative peritonitis.

Results: Metagenomic sequencing of cfDNA was able to detect and identify bacterial, viral, and eukaryotic pathogens in the peritoneal effluent from PD patients with culture-confirmed peritonitis, as well as patients with recent antibiotic usage and in cases of culture-negative peritonitis.

Limitations: Parallel cultures were not obtained in all the peritoneal effluent specimens.

Conclusions: Metagenomic cfDNA sequencing of the peritoneal effluent can identify pathogens in PD patients with peritonitis, including culture-negative peritonitis.

Conventional culture can be analytically insensitive for the detection of rare infections and for the detection of common infections in the setting of recent antibiotic usage. Indeed, patients with end-stage kidney disease on peritoneal dialysis (PD) have negative conventional cultures in 20% of suspected peritonitis cases. ¹ It is unclear whether the large proportion of unresolved cases is due to recent antibiotic use interfering with culture, infectious processes beyond peritonitis, infections due to fastidious or nonculturable organisms, or noninfectious processes.

We have recently demonstrated a “digital culture” test, based on shotgun metagenomic DNA sequencing of cell-free DNA (cfDNA), that can detect a range of bacterial, viral, and fungal infections.²,³ Importantly, we have applied this technique to body fluids that have been classically considered sterile, such as urine and amniotic fluid.⁴⁻⁶ Here, we investigate the utility of metagenomic sequencing of cfDNA in peritoneal effluent to monitor infections in PD patients.

METHODS

Description of the Study Cohort

From September 2016 to July 2018, we recruited PD patients with and without peritonitis on a continual basis for the collection of serial peritoneal effluent specimens at New York-Presbyterian Hospital/Weill Cornell Medical Center and The Rogosin Institute. The Weill Cornell Institutional Review Board approved the study (no. 1604017181), and each patient provided written informed consent. The research study was conducted according to the Declaration of Istanbul. We collected serial peritoneal effluent specimens from PD patients with clinical peritonitis (peritonitis group) and also serial peritoneal effluent specimens from PD patients who did not have clinical evidence of peritonitis in the inpatient and outpatient setting (no-peritonitis group). Peritonitis was defined using the International Society of Peritoneal Dialysis (ISPD) 2016 guidelines and was diagnosed using at least 2 of the following criteria: (1) abdominal pain and/or cloudy dialysis effluent; (2) dialysis effluent white cell count >100 per microliter with >50% polymorphonuclear white blood cells; and (3) positive dialysis effluent culture.⁷

Peritoneal Effluent Collection

Peritoneal effluent specimens were collected by drainage of fluid from the peritoneal catheter in PD patients, and at least 30 mL was collected. The peritoneal effluent specimen was subsequently centrifuged at 2,000 × g for 30 minutes and 1-mL aliquots of peritoneal effluent supernatants were collected and stored at -80 °C.

Cell-Free DNA Extraction

The 1-mL aliquots of peritoneal effluent were thawed from -80 °C storage and were centrifuged at 1,500 × g for 5 minutes. Then, 900 μL of the supernatant was transferred
Patients on peritoneal dialysis (PD) unfortunately experience peritonitis, which is commonly caused by an infection in their abdomen. Culturing the peritoneal effluent from the abdomen can usually identify the microbe suspected of causing the infection, but in some cases is unable to do so because of the limitation of the culturing assay. In this study, we examined the utility of metagenomic sequencing of peritoneal effluent cell-free DNA in PD patients with and without peritonitis. We found that the cell-free DNA sequencing assay is able to detect and identify bacterial, viral, and eukaryotic pathogens in the peritoneal effluent from PD patients with culture-confirmed peritonitis, as well as those with culture-negative peritonitis.

Library Preparation and Next-Generation Sequencing
We processed 12 μL to 26 μL of a sample using a single-stranded DNA library preparation protocol without alteration.5 Samples were indexed with 5 to 15 cycles of polymerase chain reaction amplification. DNA libraries were characterized using the Advanced Analytical Technologies Inc (AATT) fragment analyzer to confirm the absence of polymerase chain reaction primer dimers. DNA libraries were then sequenced on a NextSeq 500 using a paired-end, 2 × 75 bp kit with the substitution of Read 1 sequencing primer with the sequence (5‘-ACACTCTTTCCCTACACGACGCTCTTCC-3’). For 18 samples, a technical replicate was processed. An average of 50.7 million reads were sequenced for each sample or replicate. For 36 of the 68 samples, we detected a primer sequence used for experiments in the low biomass background correction (LBBC) pipeline.4 An average of 50.7 million reads were then merged (so read pairs were transformed to single reads) and a maximum likelihood estimator was used to estimate microbial abundance by taxa.11 A LBBC algorithm was used to remove physical and digital contaminants using the following constraints: bacteria and eukaryotes (filter at tax_ID level; coefficient of variation filter = 2.5; batch variation filter = -7; negative control multiplier filter = 50) and viruses (filter at tax_ID level; no coefficient of variation filter; batch variation filter = 8; negative control multiplier filter = 50). All samples and replicates were included in the background correction pipeline.

Antibiotic-Resistant Gene Analysis
Paired nonhuman FASTQ files were analyzed using the Resistance Gene Identifier Program using the Comprehensive Antibiotic Resistance Database v3.1.3 and CARD Resistomes & Variants v 3.0.9.12 The FASTQ files were run using the rg1 bwt command using the bowtie2 aligner and including wildcard.

Peritoneal Effluent Cell Culture
Peritoneal effluent specimens that were collected for clinical indications were cultured at Spectra Laboratories (Rockleigh, NJ) per their standard operating procedures or at New York-Presbyterian Hospital/Weill Cornell Medical Center per their standard operating procedures. Peritoneal effluent specimens which were not collected for clinical indications were cultured at New York-Presbyterian Hospital/Weill Cornell Medical Center using a combination of broth and liquid media. Peritoneal effluent was inoculated into aerobic and anaerobic blood culture vials (Becton, Dickinson, and Company [BD]) and incubated in a continuous automated blood culture instrument (BACTEC FX; BD). Specimens were also plated on tryptic soy agar with 5% sheep blood, MacConkey agar, and chocolate agar, and inoculated into thioglycolate broth (BD and Hardy Diagnostics). These media were incubated at 35 °C in 5% carbon dioxide. Finally, a portion of the fluid was inoculated onto Brucella Blood agar (Anaerobe Systems) and incubated under anaerobic conditions. Identification of microorganisms isolated in culture was performed using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (Bruker Daltonics, Inc) and antibiotic assembly/GCF_000001405.13/) using BWA-MEM.9 Human-aligned reads were analyzed for fragment length and sequencing coverage. Nonhuman reads were converted back into paired FASTQ format.
susceptibility testing was performed using broth micro-
dilution (Beckman Coulter, Inc).

Statistical Analyses

All statistical analyses were performed using the R Program
(R 3.3.3). Correlation measurements were performed us-
ing Pearson or Spearman correlations (function cor.test).
The distribution of continuous variables was analyzed us-
ing the 2-tailed Wilcoxon rank sum test and the distri-
bution of categorical variables was analyzed using the
Fisher exact test.

Data Availability

Sequencing data that support the findings of this study will
be made available in the database of Genotypes and Phe-
notypes (dbGaP) phs002251.v1.p1. Urinary cfDNA used
in data presented in Fig. 1 are available at dbGaP
phs001564.v3.p1. Local institutional review board
approval will be needed to access the data.

RESULTS

Characteristics of Peritoneal Effluent cfDNA in PD
Patients

We isolated cfDNA from 1 mL of peritoneal effluent ob-
tained from 68 specimens collected from 33 PD patients
(Fig. 1A). Among the 33 PD patients, 17 were suspected of
having clinical peritonitis and provided 46 specimens
before, during, and after the suspected clinical peritonitis
episode (peritonitis group), while 16 patients did not have
evidence of clinical peritonitis and provided 22 specimens
(no-peritonitis group). Clinical characteristics of the peri-
tonitis group and the no-peritonitis group are shown in
Table 1. Within the peritonitis group, 13 patients had
culture-confirmed peritonitis and 4 patients had culture-
negative peritonitis.

LIBRARIES WERE SEQUENCED ON THE ILLUMINA NEXTSEQ
PLATFORM AND WE OBTAINED 57.2 ± 18.7 MILLION SEQUENCES
PER SAMPLE; ON AVERAGE, 72.1% OF PAIRED-END READS ALIGNED
TO THE HUMAN GENOME. WE COMPARED THE FRAGMENTATION
PROFILE OF CFDNA IN PERITONEAL EFFLUENT TO THE FRAGMENTA-
TION PROFILES OF CFDNA IN URINE AND PLASMA, MEASURED
USING THE SAME DNA SEQUENCING AND ANALYSIS PROTOCOL
(Fig. 1B). AS PREVIOUSLY REPORTED,6,13 PLASMA CFDNA IS
PROTECTED BY NUCLEOSOME BINDING AND MOST CFDNA FRAG-
MENTS ARE LONGER THAN 100 BP (MEDIAN, 82.7%; N = 8
SAMPLES; FIG. 1B), WHILE URINARY CFDNA IS MORE DEGRADED,
WITH FEWER FRAGMENTS LONGER THAN 100 BP (MEDIAN, 44.8%;
N = 18).6,14 WE FOUND THAT CFDNA EXTRACTED FROM PERI-
TONEAL EFFLUENT, IN CONTRAST, SHARED PROPERTIES ASSOCIATED
WITH BOTH PLASMA AND URINARY CFDNA AND WAS A MIXTURE OF
BOTH LONG AND SHORT FRAGMENTS (73.8% WITH LENGTH >100
BP; N = 68; FIG. 1B).

Role of Peritoneal Effluent cfDNA in Distinguishing
Culture-Confirmed Peritonitis From No Peritonitis

We compared the concentrations of host-derived
peritoneal effluent cfDNA and microbial-derived cfDNA
in the peritonitis group and the no-peritonitis group (Fig.
1C-D). The concentration of host cfDNA was signifi-
cantly higher in specimens within 2 days of presentation in the
peritonitis group than specimens from the no-peritonitis group
(P = 2.5 × 10−10; Wilcoxon rank sum test). The concen-
tration of microbial-derived cfDNA was not
significantly different between specimens within 2 days of
presentation in the peritonitis group and specimens from the
no-peritonitis group (P = 0.34; Wilcoxon rank sum test).
We also found that the concentrations of microbial-
derived cfDNA and host-specific cfDNA were highly
 correlated for samples with more than 20 ng/mL of host-
specific cfDNA (Spearman ρ = 0.75; P = 4.5 × 10−5; n =
23; Fig. 1E). To test the ability of cfDNA to monitor

Figure 1. (A) Comparison of unfiltered cell-
free DNA (cfDNA) biomass (ng/mL peritoneal
effluent) for various culture-confirmed organ-
isms present in peritoneal effluent. Biomass
of culture-confirmed organisms in patients
0 to 2 days after diagnosis (and the first sam-
ples over that time period) compared to sam-
ples with negative culture. Dotted lines show
median values of organism biomass in 10
samples with negative cultures. (B) Heatmap
of cfDNA of common bacterial species by
peritonitis group or no-peritonitis group spec-
imens. On the y axis are peritonitis group
cases by diagnosis (top 11) and no-
peritonitis cases confirmed by culture (bottom
10), and on the x-axis are bacterial species in
the peritonitis group. The color represents
the species biomass by intensity.

Kidney Med Vol 4 | Iss 1 | January 2022

3
Figure 2. Peritoneal effluent from peritoneal dialysis (PD) patients contains cell-free DNA (cfDNA) from both human and microbial sources in cases of peritonitis. (A) Schematic illustration showing the exchange of peritoneal effluent and the collection of peritoneal effluent to recover cfDNA. (B) Fragment length distributions of cfDNA from peritoneal effluent (black) compared to cfDNA fragmentation patterns from urine (blue) and plasma (lavender). Inset: fragment length distribution of PF cfDNA aligned to the mitochondrial genome. (C) Concentration of human-derived cfDNA is shown for peritoneal effluent specimens obtained from patients in the peritonitis group and patients in the no-peritonitis group. (D) Concentration of microbial-derived cfDNA is shown for peritoneal effluent specimens from patients in the peritonitis group and patients in the no-peritonitis group. (E) Concentration of microbial and human cfDNA is compared for all samples (n = 68). (C-E) Samples collected within 0 to 2 days of peritonitis diagnosis are indicated. Abbreviations: chr., chromosome; PF, peritoneal effluent.
peritonitis, we examined the temporal dynamics of the host and microbial cfDNA concentrations relative to the day of peritonitis onset. We found that, in general, host and microbial cfDNA concentrations were elevated at the day of diagnosis and up to 2 days following antibiotic treatment. However, both returned to baseline amounts after several days (Fig S1A and B).

We also found a strong correlation between library sequencing quality (as determined by unique read fraction) and the measured concentration of peritoneal effluent cfDNA (Spearman $\rho = 0.888; P < 10^{-15}$). Given the possibility of environmental microbial DNA contamination,4,15 we evaluated cfDNA in the most common peritoneal dialysate solutions as negative controls (Dianeal 1.5%, Dianeal 2.5%, and Dianeal 4.25%; Baxter). These samples had similar characteristics to peritoneal effluent specimens with concentrations below 20 ng/mL and had a median cfDNA concentration of 8 ng/mL and a low number of unique reads (median, 11.1%). The scarcity of cfDNA in these 3 controls suggests that environmental contamination sets the limit of detection in samples with a low total DNA biomass.15

Identification of Pathogens by Peritoneal Effluent cfDNA in Both Culture-Positive Peritonitis and Culture-Negative Peritonitis

Among the peritonitis group, there were 11 culture-confirmed peritonitis events in which PD patients provided peritoneal effluent specimens within 2 days of diagnosis. These cases included: 3 Staphylococcus epidermidis, 2 Klebsiella pneumoniae, 1 Escherichia coli, 1 Staphylococcus haemolyticus, 1 Staphylococcus aureus, 1 Acinetobacter baumannii, 1 coagulase-negative Staphylococcus species, and 1 Streptococcus mitis and Streptococcus oralis case. In all cases excluding the coagulase-negative Staphylococcus species case, which was not analyzed because of a lack of species-level identification, the estimated biomass (ng/mL peritoneal effluent supernatant) of the culture-confirmed organism in the peritoneal effluent within 2 days of diagnosis was higher than the median biomass of the same species in specimens that were confirmed to be culture-negative in the no-peritonitis group (Fig. 2A). The cfDNA abundances of common bacterial species are also graphically represented by culture-confirmed peritonitis and culture-negative peritonitis cases (Fig. 2B, Table S1). Correlational analyses were also performed between the host cfDNA and white blood cell count.

| Characteristic | Peritonitis Group | No-Peritonitis Group | P Value |
|----------------|-------------------|----------------------|---------|
| Age in years, median (IQR) | 54 (42-63) | 58 (52-69) | 0.35 |
| Female gender | 11 (65%) | 9 (56%) | 0.73 |
| Race | | | |
| White | 6 (35%) | 6 (38%) | 0.99 |
| Black | 5 (29%) | 5 (31%) | 0.99 |
| Asian | 1 (6%) | 2 (13%) | 0.60 |
| American Indian | 0 (0%) | 1 (6%) | 0.48 |
| Other | 5 (29%) | 2 (13%) | 0.40 |
| Hypertension | 17 (100%) | 14 (88%) | 0.23 |
| Diabetes mellitus | 9 (53%) | 6 (38%) | 0.49 |
| Hyperlipidemia | 11 (65%) | 7 (44%) | 0.30 |

Note: P values were calculated using a Wilcoxon signed rank test or Fisher exact test. All laboratory values were obtained at the time of the first peritoneal effluent specimen collection.

Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cycling peritoneal dialysis; IQR, interquartile range; PD, peritoneal dialysis.
cell concentration, and there was a significant positive correlation of Spearman’s ρ of 0.78 ($P < 0.001$; Fig S2). We also analyzed the antibiotic-resistant genes present in the 11 culture-confirmed peritonitis cases and found a number of antibiotic-resistant genes within each of the specimens (Fig S3). However, given the low sample size of antimicrobial susceptibility testing patterns (7 of 11 were available), we were not able to make correlations between cfDNA and antimicrobial susceptibility patterns.

A major challenge for cfDNA metagenomic sequencing is its relatively poor specificity due to alignment noise and environmental contamination. To overcome this limitation, we recently developed LBBC, a metagenomics noise-filtering tool informed by the uniformity of the coverage of microbial genomes and the batch variation in the absolute abundance of microbial cfDNA. We applied LBBC to all 68 data sets and 18 replicates and aggregated and visualized the data at the species level (Fig 3A). Noise filtering by LBBC improved the specificity of the metagenomics analysis without greatly reducing the sensitivity. The exceptions for identification included: a case of $S$ oralis and $S$ mitis, a case of $A$ baumannii, a case of $E$ coli, a case of coagulase-negative $S$ epidermidis species, and a case of $S$ epidermidis for which metagenomic hits were filtered out by LBBC.

Importantly, in the $K$ pneumoniae and $S$ haemolyticus cases, cfDNA sequencing detected the same organisms in culture-confirmed peritonitis even after antibiotic therapy and even though the conventional cultures were negative after antibiotic therapy but positive before antibody therapy. Our data suggest that cfDNA within 2 days of peritonitis can still be diagnostic of peritonitis despite recent antibiotic therapy and the conventional culture being negative in the setting of antibiotic therapy.

In the peritonitis group, there were 4 patients with a total of 5 episodes of culture-negative peritonitis who were treated as if they had clinical peritonitis, and 1 culture-confirmed PD patient who subsequently developed culture-negative peritonitis. In 1 patient with culture-negative peritonitis, the top 2 microbial species identified were Enterococcus faecalis and Parabacteroides distasonis. This patient did not improve after antibiotic therapy for.

---

**Figure 3.** Metagenomic sequencing of cell-free DNA from peritoneal effluent reveals presence of pathogens in the peritoneum. (A) A biomass of various microbial organisms detected in samples across the cohort is shown. (B) In select cases, the fragment length histogram of reads aligning to $Klebsiella pneumoniae$ (culture confirmed in peritoneal effluent), $Parabacteroides distasonis$ (culture confirmed from gallbladder), $Saccharomyces cerevisiae$ (not recovered in culture), and cytomegalovirus (no culture/polymerase chain reaction) are shown. Vertical lines represent median value in the range of 25 to 300 bp. (C) For organisms in panel B, sequencing coverage across respective microbial genomes is shown as the number of read alignments per bin (bin size variable; 50 total bins per plot). Abbreviations: CMV, cytomegalovirus; HHV, human herpesvirus.
presumed peritonitis and eventually had a cholecystotomy for presumed cholecystitis. The cultures from the cholecystotomy drain grew *E. faecalis* and *P. distasonis*. Given the ability of *E. faecalis* and *P. distasonis* to grow efficiently on conventional media, it is likely that the patient truly had culture-negative peritonitis and that the detected cfDNA diffused from the gallbladder. Our limited data suggest that peritoneal effluent cfDNA can diagnose infections beyond peritonitis. In another PD patient with culture-negative peritonitis, while microbial cfDNA was not initially detected above background, an elevated amount of *E. coli* was detected 11 days after presentation and after antibiotic treatment. In one other patient, low levels of *P. distasonis* and *P. vulgaris* were detected, and in the 2 other patients, there was no identified pathogen above background.

**Identification of Viral and Eukaryotic Pathogenic cfDNA in Peritoneal Effluent**

We further detected cfDNA derived from human viruses and bacteriophages in samples from patients with and without peritonitis (Fig 3A). In the case of the culture-negative peritonitis in which cfDNA sequencing revealed the presence of *E. coli*, we detected cfDNA from an enterobacteria phage cfDNA (3.1 pg/mL). In another sample from a patient with diagnosed *E. coli* peritonitis, we found a high burden of human herpesvirus (HHV-6, >2 pg/mL). In another PD patient who presented for a routine visit and no evidence of clinical peritonitis, we observed a high burden of human cytomegalovirus (1.1 pg/mL). We also observed cfDNA derived from fungi in a specimen from a patient with a history of recent peritonitis. Interestingly, we observed a high level of *Saccharomyces cerevisiae* cfDNA at 15 days after detection of *Klebsiella pneumoniae* peritonitis. The patient was treated with fluconazole prophylactically after the peritonitis episode, but eventually, the patient had her catheter removed due to recurrent peritonitis and cyst infections. To further confirm the identification of *S. cerevisiae*, we compared BLAST reads in a paired-end context (see Methods). We found that *S. cerevisiae* genome fragments were distributed, as expected, with a median fragment length exceeding 90 bp and a local peak at approximately 144 bp, representing the length of DNA in the yeast nucleosome (Fig 3B).16 We compared this to cfDNA aligned to *K. pneumoniae*, *P. distasonis*, and cytomegalovirus, and found high median length values for all cases (Fig 3B).

**DISCUSSION**

We report the first in-depth analysis of the properties of cfDNA in peritoneal effluent and a study of the utility of metagenomic sequencing of cfDNA in peritoneal effluent for screening infections within the peritoneal cavity. We found that peritoneal effluent cfDNA sequencing can not only detect pathogens consistent with culture-confirmed peritonitis in the majority of cases, but also detect bacterial, viral, and fungal organisms in culture-negative peritonitis and after antibiotic therapy, demonstrating the power of cfDNA-based diagnostics beyond conventional culture.

Positive body fluid cultures are among the criteria for diagnosing peritonitis by the ISPD 2016 guidelines.7 While culture can diagnose infection in a majority of cases, cultures are negative in approximately 20% of PD patients, leading to patients being presumptively treated for culture-positive peritonitis.1 In these particularly difficult cases, metagenomic sequencing of cfDNA may have several advantages over conventional culture. First, antibiotics that can diffuse into the peritoneum or are directly instilled into the peritoneum can interfere with the culturing process. As shown in our study, we detected cfDNA from the same pathogen in culture-confirmed cases within 2 days of antibiotic therapy even though corresponding peritoneal effluent cultures were negative. Second, the inflammatory process in the peritoneum can be related to processes beyond infection of the peritoneal effluent. We have presented a case in which the nidus of infection was the gallbladder in a PD patient who was treated for presumed peritonitis and the bacterial cfDNA in the gallbladder likely diffused into the peritoneal cavity, and both suspected bacterial pathogens were identified using cfDNA sequencing of the peritoneal effluent. It is conceivable that PD patients with culture-negative peritonitis have abdominal infections beyond peritonitis and that cfDNA sequencing may identify suspected pathogens. Given the expected low biomass of the peritoneal effluent, we have implemented a filtering process that eliminates background contamination. While this process eliminates many organisms that are likely contaminants in the processing steps, it does filter out some of the culture-confirmed positive organisms. A larger study to maximize the filtering process for false positives but minimize the elimination of true positives is needed.

Peritoneal effluent cfDNA sequencing further identified viral and fungal DNA in peritoneal effluent that was otherwise undetected in PD patients. Cytomegalovirus (HHV-5) was identified in a PD patient who presented to the clinic for routine follow-up and Roseolovirus (HHV-6) was identified in a patient with concurrent *E. coli* peritonitis. In a patient who received treatment for *K. pneumoniae* peritonitis and antifungal prophylaxis with fluconazole, metagenomic cfDNA sequencing identified *S. cerevisiae*. In this case, we attempted to culture the *S. cerevisiae* from a stored peritoneal effluent specimen using conventional fungal culture, but we were unable to recover *S. cerevisiae* in culture. The detection of these specific viral and fungal elements, however, raises the question of whether these pathogens are the cause of disease. In the case of a PD patient with detectable cytomegalovirus cfDNA, the patient was not symptomatic, and so our assay might have detected the latent virus. For the PD patient with detectable *S. cerevisiae*, it is possible that the *S. cerevisiae* cfDNA was diffusing from the gut. It is also possible that diffusion of cfDNA occurs from the plasma to peritoneal fluid because of increased peritoneal permeability and is not present in the abdominal...
cavity. While peritoneal effluent cfdNA sequencing may be able to detect microbial cfdNA at high resolution, further studies that concurrently examine plasma cfdNA are needed to better understand whether the microbes detected by this technology are causing the diseased state.

Next-generation sequencing of peritoneal effluent cfdNA has the potential to aid in the diagnosis of challenging cases, such as culture-negative peritonitis or recurrent peritonitis, and to predict relapse of peritonitis. When compared to conventional culture, the widespread adoption of such a technique may be difficult given the complexity of analyses, especially in resource-limited settings. However, many advances in next-generation sequencing technology have led to decreased costs, decreased turnaround times, and increased portability. Nanopore sequencers, for example, can be purchased for approximately $1,000 US dollars (in 2021) and can provide real-time sequencing data with a small-footprint, portable device. Indeed, a recent study by Gu et al. reported on using Nanopore sequencing for body fluids, and reported a median 50-minute sequencing time and a 6-hour sample-to-answer time.

In summary, our study identifies peritoneal effluent cfdNA sequencing as a novel method to characterize both culture-positive and culture-negative peritonitis in PD patients. Further studies are needed to validate the utility of peritoneal effluent cfdNA sequencing in challenging cases of culture-negative peritonitis and current peritonitis.

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Figure S1: Human cfdNA and microbial cfdNA in peritonitis cases over time.

Figure S2: Human cfdNA biomass correlates with peritoneal fluid white blood cell.

Figure S3: Antibiotic resistant profiles in peritonitis cases.

Item S1: Potential adapters present in sample.

Table S1: cfdNAS species biomass are represented in the 11 culture-confirmed peritonitis cases and the 10 no peritonitis cases confirmed by culture.

ARTICLE INFORMATION

Authors’ Full Names and Academic Degrees: Philip Burnham, PhD, Fanny Chen, BS, Alexandre P. Cheng, PhD, Vesh Srivatana, MD, Lisa T. Zhang, MD, Emmanuel Edusei, BS, Shady Albakry, BA, Brittany Botticelli, BA, Xunxi Guo, MD, Amanda Renaghan, MD, Jeffrey Silberzweig, MD, Darshana M. Dadhania, MD, Joan S. Lenz, PhD, Michael Heyang, BS, Illyan D. Iliev, PhD, Joshua A. Hayden, PhD, Lars F. Westblade, PhD, Iwijn De Vlaminck, PhD, and John R. Lee, MD.

Authors’ Affiliations: Meining School of Biomedical Engineering, Cornell University, Ithaca, NY (PB, FC, APC, JSL, MH, IDV); The Rogosin Institute, New York, NY (VS, JRL); Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, NY (LTZ, EE, SA, BB, XG, AR, DMD, JRL); Department of Transplantation Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, New York, NY (DMD, JRL); Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY (IDI); Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY (JAH, LFW); Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY (LFW); Department of Bioengineering, University of Pennsylvania, Philadelphia, PA (PB, current affiliation); and Department of Chemistry, Norton Healthcare, Louisville, KY (JAH, current affiliation).

Address for Correspondence: Iwijn De Vlaminck, Meining School of Biomedical Engineering, Cornell University, Weill Hall Room 301, Ithaca, NY, 14853. Email: vlamink@cornell.edu or John R. Lee, Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, 525 E. 68th Street Box 3, New York, NY, 10065. Email: jrl2002@med.cornell.edu

Authors’ Contributions: Study design: PB, IDV, JAH, LFW, JRL; sample collection and clinical metadata: VS, LTZ, EE, SA, BB, XG, AR, JS, JRL; conducted experiments: PB, FC, MH, JSL, LFW; data analysis: PB, FC, APC, DMD, IDV, IDI, JRL. IDV and JRL contributed equally to this work. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: This work was supported by the National Kidney Foundation Young Investigator Research Grant (to JRL) and US National Institutes of Health grants R21AI133331 (to IDV and JRL), R21AI124237 (to IDV), DP2AI138242 (to IDV), R01AI146165 (to IDV), RO1AI151059 (to DMD and IDV), and R21AI164093 (to IDV and JRL). PB was supported by a National Science Foundation Graduate Research Fellowship Program (NSF GRFP), DGE-1144153. APC is supported by the National Sciences and Engineering Research Council of Canada (401236174) fellowship.

Financial Disclosure: PB was supported by an NSF GRFP, DGE-1144153. APC is supported by the National Sciences and Engineering Research Council of Canada (401236174) fellowship. PB, APC, DMD, IDV, and JRL hold patent US-2020-0048713-A1, titled “Methods of Detecting Cell-Free DNA in Biological Samples.” PB is an employee, IDV is an advisor/cofounder, and both PD and IDV are shareholders of Kanvas Biosciences. VS reports receiving speakers’ fees from Baxter Healthcare. JS receives consulting fees from Alkahest, Bayer, and Kaneka. LFW receives research support from Accelerate Diagnostics, Inc, BioFire Diagnostics, LLC, Hardy Diagnostics, and Roche Molecular Systems, Inc, and consulting fees from Roche Molecular Systems, Inc, Shionogi, Inc, and Taib Biomedical. DMD receives consulting fees from Veloxis Pharmaceutical, Inc and Allovir, Inc JRL receives research support under an investigator-initiated research grant from BioFire Diagnostics, LLC.

Acknowledgments: We thank Peter Schweitzer and his team at the Cornell University Biotechnology Resource Center for help with sequencing. We thank members of the De Vlaminck lab for helpful comments and discussion. We thank Dr. Manikkam Suthanthiran for his overall guidance in this project.

Peer Review: Received April 01, 2021, as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Editor-in-Chief. Accepted in revised form August 30, 2021.

REFERENCES

1. Kocyigit I, Unal A, Karademir D, et al. Improvement in culture-negative peritoneal dialysis-related peritonitis: a single center’s experience. Perit Dial Int. 2012;32(4):476-478.
2. De Vlaminck I, Valentine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6(241):241ra77.
3. De Vlaminck I, Khush KK, Strehl C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell. 2013;155(5):1178-1187.
4. Burnham P, Gomez-Lopez N, Heyang M, et al. Separating the signal from the noise in metagenomic cell-free DNA sequencing. *Microbiome*. 2020;8(1):18.

5. Cheng AP, Burnham P, Lee JR, et al. A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection. *Proc Natl Acad Sci U S A*. 2019;116(37):18738-18744.

6. Burnham P, Dadhania D, Heyang M, et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. *Nat Commun*. 2018;9(1):2412.

7. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. *Perit Dial Int*. 2016;36(5):481-508.

8. Burnham P, Kim MS, Agbor-Enoh S, et al. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. *Sci Rep*. 2016;6:27859.

9. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009;25(14):1754-1760.

10. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol*. 1990;215(3):403-410.

11. Xia LC, Cram JA, Chen T, Fuhrman JA, Sun F. Accurate genome relative abundance estimation based on shotgun metagenomic reads. *PLoS One*. 2011;6(12):e27992.

12. Alcock BP, Raphenya AR, Lau TTY, et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res*. 2020;48(D1):D517-D525.

13. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. *Cell*. 2016;164(1-2):57-68.

14. Tsui NB, Jiang P, Chow KC, et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. *PLoS One*. 2012;7(10):e48319.

15. de Goffau MC, Lager S, Salter SJ, et al. Recognizing the reagent microbiome. *Nat Microbiol*. 2018;3(8):851-853.

16. Ozonov EA, van Nimwegen E. Nucleosome free regions in yeast promoters result from competitive binding of transcription factors that interact with chromatin modifiers. *PLoS Comput Biol*. 2013;9(8):e1003181.

17. Gu W, Deng X, Lee M, et al. Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids. *Nat Med*. 2021;27(1):115-124.